Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
Medtronic
McKesson
Colorcon

Last Updated: December 6, 2022

CLINICAL TRIALS PROFILE FOR SPIRIVA


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Spiriva

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00144196 ↗ 12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD) Completed Boehringer Ingelheim Phase 4 2004-03-01 To show that treatment with tiotropium inhalation capsules (18 μg q.d.) via HandiHaler® improves lung function in patients with mild COPD according to Swedish guidelines.
NCT00144326 ↗ A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (C Completed Boehringer Ingelheim Phase 3 2003-07-01 The objective of this study is to determine if tiotropium (Spiriva, Bromuro de Tiotropio) 18 mcg once daily by oral inhalation compared to placebo increases the magnitude of daily physical activity observed in COPD patients, measured using an accelerometer.
NCT00144339 ↗ Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients Completed Boehringer Ingelheim Phase 3 2002-12-01 The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.
NCT00157235 ↗ Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients Completed Boehringer Ingelheim Phase 3 2002-09-01 The objective of this trial is to determine whether tiotropium inhalation capsules (Spiriva, Bromuro de Tiotropio), compared to placebo, enhances the improvement in exercise tolerance seen in patients with chronic obstructive pulmonary disease (COPD) who participate in pulmonary rehabilitation.
NCT00239408 ↗ Spiriva (Tiotropium Bromide) Assessment of FEV1 - (SAFE-Portugal). Completed Boehringer Ingelheim Phase 4 2002-12-01 Evaluate whether the effect of inhaled tiotropium bromide on the change in trough forced expiratory volume (FEV1), compared to placebo in patients with chronic obstructive pulmonary disease (COPD), is affected by smoking status.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Spiriva

Condition Name

Condition Name for Spiriva
Intervention Trials
Pulmonary Disease, Chronic Obstructive 41
Chronic Obstructive Pulmonary Disease 21
COPD 16
Chronic Obstructive Pulmonary Disease (COPD) 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Spiriva
Intervention Trials
Pulmonary Disease, Chronic Obstructive 75
Lung Diseases 72
Lung Diseases, Obstructive 43
Chronic Disease 41
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Spiriva

Trials by Country

Trials by Country for Spiriva
Location Trials
United States 559
Canada 62
Germany 32
Australia 30
China 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Spiriva
Location Trials
South Carolina 30
Florida 28
North Carolina 26
California 26
Ohio 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Spiriva

Clinical Trial Phase

Clinical Trial Phase for Spiriva
Clinical Trial Phase Trials
Phase 4 34
Phase 3 27
Phase 2/Phase 3 2
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Spiriva
Clinical Trial Phase Trials
Completed 91
Terminated 5
Unknown status 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Spiriva

Sponsor Name

Sponsor Name for Spiriva
Sponsor Trials
Boehringer Ingelheim 48
Pearl Therapeutics, Inc. 9
Pfizer 6
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Spiriva
Sponsor Trials
Industry 107
Other 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
AstraZeneca
Baxter
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.